Form 4: Twist Bioscience CEO Emily Leproust Reports Stock Sale to Cover Tax Obligations
SEC Form 4 Filing
Emily Leproust, CEO of Twist Bioscience, sold 1,132 shares of common stock on April 2, 2024, to cover tax withholding obligations related to the vesting of Restricted Stock Units.
Summary
- On April 2, 2024, Emily M. Leproust, CEO of Twist Bioscience, sold 1,132 shares of common stock at a price of $32.736 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of Restricted Stock Units.
- Following the transaction, Leproust directly owns 514,149 shares of Twist Bioscience common stock.
- Leproust also holds various employee stock options with different exercise prices and expiration dates.
- These options include those exercisable at $5.95, $8.82, $26.66, $23.33, and $67.85.
- Some options are immediately exercisable, while others vest over time based on continued service.
- Performance stock options granted on September 1, 2020, vested on December 19, 2022, after meeting performance criteria.
Sentiment
Score: 5
Explanation: The document is a standard SEC filing detailing a stock sale for tax purposes, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.
Comparison to Industry Standards
- Tracking insider transactions is a common practice in financial analysis to gauge management's sentiment and potential future performance.
- Comparing Leproust's transactions with those of executives at peer companies like Agilent or Illumina could provide insights into relative valuation and growth expectations.
- However, this transaction appears to be a routine 'sell to cover' for tax obligations, which is a common and generally neutral event.
Stakeholder Impact
- The stock sale may have a minor, temporary impact on the stock price, but is unlikely to significantly affect long-term shareholder value.
- Employees holding stock options may be interested in the exercise prices and vesting schedules outlined in the filing.
Key Dates
| Date | Description |
|---|---|
| 09/01/2016 | 25% of shares subject to $5.95 option vested |
| 09/28/2017 | 10% of shares subject to $8.82 option vested |
| 09/28/2018 | 15% of shares subject to $8.82 option vested |
| 10/31/2019 | 20% of shares subject to $26.66 option vested |
| 09/01/2020 | Performance stock options granted |
| 10/24/2020 | 25% of shares subject to $23.33 option vested |
| 12/19/2022 | Performance stock options vested |
| 04/02/2024 | Leproust sold 1,132 shares at $32.736 |
| 04/04/2024 | Date of Form 4 filing |
| 09/28/2025 | Expiration date for options exercisable at $5.95 |
| 09/28/2027 | Expiration date for options exercisable at $8.82 |
| 11/18/2028 | Expiration date for options exercisable at $26.66 |
| 10/23/2029 | Expiration date for options exercisable at $23.33 |
| 08/31/2030 | Expiration date for options exercisable at $67.85 |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.